Royalty Pharma (RPRX) — insider trading
Health Care · NASDAQ
Royalty Pharma (RPRX) has 43 reported SEC Form 4 insider transactions in our data, including 21 open-market sales among the most recent 43 (latest 2026-10-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Urist Marshall | Officer (EVP, Research & Investments) | Open-market sale | 4,126 | $57.10 | $235.6K | Form 4 |
| 2026-09-30 | Bassler Bonnie L | Director | Grant / award / vesting | 642 | $58.41 | $37.5K | Form 4 |
| 2026-09-28 | Urist Marshall | Officer (EVP, Research & Investments) | Open-market sale | 4,126 | $57.88 | $238.8K | Form 4 |
| 2026-09-22 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 3,927 | $58.93 | $231.4K | Form 4 |
| 2026-09-22 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 96,073 | $58.51 | $5.62M | Form 4 |
| 2026-08-19 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Bona fide gift | 16,800 | — | $0 | Form 4 |
| 2026-08-18 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 100,000 | $59.97 | $6.00M | Form 4 |
| 2026-08-13 | Coyne Terrance P. | Officer (EVP & CFO) | Open-market sale | 1,772 | $59.14 | $104.8K | Form 4 |
| 2026-08-13 | Coyne Terrance P. | Officer (EVP & CFO) | Open-market sale | 9,230 | $58.59 | $540.8K | Form 4 |
| 2026-08-07 | Urist Marshall | Officer (EVP, Research & Investments) | Bona fide gift (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-08-07 | Coyne Terrance P. | Officer (EVP & CFO) | Bona fide gift (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-08-07 | Legorreta Pablo G. | Director, Officer (CEO, Chairman of the Board) | Bona fide gift (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-08-05 | Urist Marshall | Officer (EVP, Research & Investments) | Grant / award / vesting | 8,252 | — | $0 | Form 4 |
| 2026-08-05 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Grant / award / vesting | 11,002 | — | $0 | Form 4 |
| 2026-08-05 | Coyne Terrance P. | Officer (EVP & CFO) | Grant / award / vesting | 11,002 | — | $0 | Form 4 |
| 2026-08-05 | Legorreta Pablo G. | Director, Officer (CEO, Chairman of the Board) | Grant / award / vesting | 65,216 | — | $0 | Form 4 |
| 2026-07-01 | Urist Marshall | Officer (EVP, Research & Investments) | Open-market sale | 9,099 | $55.88 | $508.5K | Form 4 |
| 2026-06-30 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 600 | $57.09 | $34.3K | Form 4 |
| 2026-06-30 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 29,400 | $56.44 | $1.66M | Form 4 |
| 2026-06-30 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 2,554 | $57.10 | $145.8K | Form 4 |
| 2026-06-30 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 97,446 | $56.50 | $5.51M | Form 4 |
| 2026-06-30 | Bassler Bonnie L | Director | Grant / award / vesting | 689 | $54.40 | $37.5K | Form 4 |
| 2026-06-24 | Urist Marshall | Officer (EVP, Research & Investments) | Open-market sale | 9,098 | $55.18 | $502.1K | Form 4 |
| 2026-06-23 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 117,592 | $54.47 | $6.41M | Form 4 |
| 2026-06-23 | Hite Christopher | Officer (EVP & Chairman, Partnering) | Open-market sale | 32,408 | $54.11 | $1.75M | Form 4 |
| 2026-06-05 | Bassler Bonnie L | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | Coric Vlad | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | Engelbert Catherine M. | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | Ho Carole | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | HODGSON DAVID C | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | LOVE TED W | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | Norden Gregory | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-06-05 | WEATHERMAN ELIZABETH H | Director | Grant / award / vesting | 4,545 | — | $0 | Form 4 |
| 2026-05-26 | Coyne Terrance P. | Officer (EVP & CFO) | Open-market sale | 64,399 | $53.98 | $3.48M | Form 4 |
| 2026-05-20 | Urist Marshall | Officer (EVP, Research & Investments) | Open-market sale | 13,684 | $52.75 | $721.8K | Form 4 |
| 2026-05-14 | Norden Gregory | Director | Open-market sale | 3,045 | $53.00 | $161.4K | Form 4 |
| 2026-05-14 | Urist Marshall | Officer (EVP, Research & Investments) | Open-market sale | 13,684 | $53.06 | $726.1K | Form 4 |
| 2026-05-06 | Urist Marshall | Officer (EVP, Research & Investments) | Grant / award / vesting | 18,197 | — | $0 | Form 4 |
| 2026-05-06 | Hite Christopher | Officer (EVP & Vice Chairman) | Grant / award / vesting | 24,263 | — | $0 | Form 4 |
| 2026-05-06 | Coyne Terrance P. | Officer (EVP & CFO) | Grant / award / vesting | 24,263 | — | $0 | Form 4 |
| 2026-05-06 | Legorreta Pablo G. | Director, Officer (CEO, Chairman of the Board) | Grant / award / vesting | 143,821 | — | $0 | Form 4 |
| 2026-04-28 | Coyne Terrance P. | Officer (EVP & CFO) | Open-market sale | 1,875 | $49.78 | $93.3K | Form 4 |
| 2026-04-28 | Coyne Terrance P. | Officer (EVP & CFO) | Open-market sale | 32,916 | $49.78 | $1.64M | Form 4 |
Ask the chat about RPRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Royalty Pharma (RPRX).
Last updated 2026-10-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.